At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 158 enrolled
Drug / intervention
SHR-1819 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacokinetics of SHR-1819 Injection in Adults With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating SHR-1819 and Placebo for Moderate to Severe Atopic Dermatitis. Completed, enrolled 158 participants across 1 site.
Detailed Summary
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Atopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartOct 2022
Primary CompletionSep 2023
Study CompletionNov 2023
TodayJul 2026
First PostedSep 22, 2022
Enrollment StartOct 8, 2022
Primary CompletionSep 15, 2023
Study CompletionNov 23, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.8 years ago
Interventions
SHR-1819drug
Treatment group A: SHR-1819 injection dose 1; Treatment group B: SHR-1819 injection dose 2; Treatment group C：SHR-1819 injection dose 3.
Placebodrug
Treatment group D: placebo